Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drugs in Development, 2021

November 2021 | 51 pages | ID: C220D1186523EN
Global Markets Direct

Abstracts

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drugs in Development, 2021

SUMMARY

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Cell Division Cycle 7 Related Protein Kinase - Drugs in Development, 2021, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylates substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Solid Tumor, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, Breast Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemia, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Rectal Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Uterine Cancer.

Furthermore, this report also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
• The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Overview
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Carna Biosciences Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Eli Lilly and Co
Lin Bioscience Inc
Millennium Pharmaceuticals Inc
NMS Group SpA
Schrodinger Inc
Takeda Pharmaceutical Co Ltd
Zai Lab Ltd
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles
AS-0141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3143921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSK-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDGR-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
simurosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDC7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDc7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TQB-3824 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-2309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Products
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2021: Schr?dinger reports preclinical data on novel, selective CDC7 inhibitors presented at American Association for Cancer Research Annual Meeting
Mar 30, 2021: Schr?dinger to host webcast in conjunction with presentation of preclinical data for its CDC7 program at virtual AACR annual meeting
Mar 10, 2021: Schrodinger announces preclinical data for CDC7 program to be presented at AACR Virtual Annual Meeting 2021
Apr 03, 2019: Sierra reports late-breaking SRA141 preclinical data in poster at AACR 2019
Feb 27, 2019: Sierra Oncology announces late-breaking poster presentation at AACR 2019 for SRA141 preclinical data
Nov 13, 2018: Sierra Oncology reports SRA141 preclinical efficacy at EORTC-NCI-AACR symposium
Nov 09, 2018: Successful Completion of IND filing with FDA for SRA141
Apr 24, 2018: Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Feb 27, 2018: Sierra Oncology Provides Update on SRA141
Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York
Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Carna Biosciences Inc, 2021
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Lin Bioscience Inc, 2021
Pipeline by Millennium Pharmaceuticals Inc, 2021
Pipeline by NMS Group SpA, 2021
Pipeline by Schrodinger Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Zai Lab Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021